Integrative Management of Cancer Pain: A Scoping Review of the Literature

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-05-03 DOI:10.1002/cam4.70833

Brieze K. Bell, Jaeyoon Cha, Kathleen A. Cavanaugh, David L. O'Riordan, Michael W. Rabow, Adrienne K. Yang, Sohil Patel, Sa Heen Park, Megan K. McGrath, Evans M. Whitaker, Sarah S. Nouri, Stephanie W. Cheng

{"title":"Integrative Management of Cancer Pain: A Scoping Review of the Literature","authors":"Brieze K. Bell, Jaeyoon Cha, Kathleen A. Cavanaugh, David L. O'Riordan, Michael W. Rabow, Adrienne K. Yang, Sohil Patel, Sa Heen Park, Megan K. McGrath, Evans M. Whitaker, Sarah S. Nouri, Stephanie W. Cheng","doi":"10.1002/cam4.70833","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Cancer-related pain is common and debilitating. Patients frequently use integrative medicine therapies to manage this, though safety and efficacy evidence is incomplete. This scoping review aims to characterize the state of integrative cancer pain therapy (ICPT) and identify priorities for future research.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Following PRISMA guidelines, we searched PubMed, Embase, Web of Science, PsycINFO, CINAHL, and Cochrane for ICPT studies published between January 1, 1975 and May 26, 2022. Study findings were extracted and analyzed using descriptive statistics and thematic analysis. Interventions were categorized as follows: Whole Systems of Medicine (WSM); Mind–body Medicine (MBM); Botanicals and Supplements (BAS); and Manual Therapies (MT). Quality appraisal was performed using the Downs and Black checklist. Efficacy was “positive” if there were statistically significant differences between study arms (<i>p</i> < 0.05) favoring ICPT.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 1246 studies reviewed, 151 met inclusion criteria; 63.5% were excellent or good quality, and 68.9% were RCTs; 122 studies (80.7%) were published since 2010. Studies occurred in 24 countries, in variable settings, among participants with a wide range of cancers, disease status, and age ranges. Studies investigating WSM and MBM interventions were most frequent (35.7% for each), MT (20.59%), and BAS (7.9%). Overall, of the included studies, 127 (84.1%) found that the ICPT intervention reduced pain.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Studies on ICPT are increasingly common, and the majority of ICPT interventions demonstrated a positive impact on cancer pain. Future rigorous research should compare efficacy across integrative and biomedical interventions and explore how to incorporate evidence-based ICPT into standard cancer treatment.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70833","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70833","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cancer-related pain is common and debilitating. Patients frequently use integrative medicine therapies to manage this, though safety and efficacy evidence is incomplete. This scoping review aims to characterize the state of integrative cancer pain therapy (ICPT) and identify priorities for future research.

Methods

Following PRISMA guidelines, we searched PubMed, Embase, Web of Science, PsycINFO, CINAHL, and Cochrane for ICPT studies published between January 1, 1975 and May 26, 2022. Study findings were extracted and analyzed using descriptive statistics and thematic analysis. Interventions were categorized as follows: Whole Systems of Medicine (WSM); Mind–body Medicine (MBM); Botanicals and Supplements (BAS); and Manual Therapies (MT). Quality appraisal was performed using the Downs and Black checklist. Efficacy was “positive” if there were statistically significant differences between study arms (p < 0.05) favoring ICPT.

Results

Among 1246 studies reviewed, 151 met inclusion criteria; 63.5% were excellent or good quality, and 68.9% were RCTs; 122 studies (80.7%) were published since 2010. Studies occurred in 24 countries, in variable settings, among participants with a wide range of cancers, disease status, and age ranges. Studies investigating WSM and MBM interventions were most frequent (35.7% for each), MT (20.59%), and BAS (7.9%). Overall, of the included studies, 127 (84.1%) found that the ICPT intervention reduced pain.

Conclusions

Studies on ICPT are increasingly common, and the majority of ICPT interventions demonstrated a positive impact on cancer pain. Future rigorous research should compare efficacy across integrative and biomedical interventions and explore how to incorporate evidence-based ICPT into standard cancer treatment.

Abstract Image

查看原文本刊更多论文

癌症疼痛的综合治疗：文献综述

癌症相关的疼痛很常见，而且使人虚弱。尽管安全性和有效性证据尚不完整，但患者经常使用中西医结合疗法来控制这种情况。本综述旨在描述综合癌症疼痛治疗（ICPT）的现状，并确定未来研究的重点。方法按照PRISMA指南，检索PubMed、Embase、Web of Science、PsycINFO、CINAHL和Cochrane，检索1975年1月1日至2022年5月26日之间发表的ICPT研究。利用描述性统计和专题分析对研究结果进行提取和分析。干预措施分类如下：医学整体系统（WSM）；身心医学；植物制剂和补充剂；和手工疗法（MT）。使用Downs和Black检查表进行质量评估。如果研究组间支持ICPT的差异有统计学意义（p < 0.05），则疗效为“阳性”。结果1246项研究中，151项符合纳入标准；优良率为63.5%，随机对照试验为68.9%；2010年以来共发表122篇研究（80.7%）。研究在24个国家的不同环境中进行，参与者的癌症、疾病状况和年龄范围都很广。调查WSM和MBM干预的研究最为常见（各占35.7%），其次是MT（20.59%）和BAS（7.9%）。总的来说，在纳入的研究中，127项（84.1%）发现ICPT干预减轻了疼痛。关于ICPT的研究越来越普遍，大多数ICPT干预措施对癌症疼痛有积极影响。未来严谨的研究应该比较综合干预和生物医学干预的疗效，并探索如何将基于证据的ICPT纳入标准的癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.